Page last updated: 2024-10-31

ml 7 and Atherogenesis

ml 7 has been researched along with Atherogenesis in 4 studies

ML-7 : An N-sulfonyldiazepane resullting from the formal condensation of 5-iodo-1-naphthylsulfonic acid with one of the nitrogens of 1,4-diazepane. It is a selective inhibitor of myosin light chain kinase (EC 2.7.11.18).

Research Excerpts

ExcerptRelevanceReference
"HFD-fed rabbits showed typical atheromatous lesions and endothelial hyperpermeability, and these lesions could be partly reversed following ML7 therapy."1.56Myosin light chain kinase inhibitor ML7 improves vascular endothelial dysfunction and permeability via the mitogen-activated protein kinase pathway in a rabbit model of atherosclerosis. ( Ding, J; Ding, Y; Gui, S; Li, L; Li, Z; Meng, S; Wang, D; Wang, Y; Wei, W; Zhou, Q; Zhu, H, 2020)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Ding, J1
Li, Z1
Li, L1
Ding, Y1
Wang, D1
Meng, S1
Zhou, Q3
Gui, S1
Wei, W1
Zhu, H2
Wang, Y4
Wang, J1
Zhang, C1
Li, C1
Zhao, D1
Li, S1
Ma, L1
Cui, Y1
Wei, X1
Zhao, Y1
Gao, Y1
Zhu, HQ1
Wang, XB1
Han, JX1
Hu, ZP1
Gui, SY1
Cheng, X1
Wang, X1
Wan, Y1

Other Studies

4 other studies available for ml 7 and Atherogenesis

ArticleYear
Myosin light chain kinase inhibitor ML7 improves vascular endothelial dysfunction and permeability via the mitogen-activated protein kinase pathway in a rabbit model of atherosclerosis.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 128

    Topics: Animals; Aorta, Thoracic; Atherosclerosis; Azepines; Diet, High-Fat; Disease Models, Animal; Endothe

2020
MicroRNA-92a promotes vascular smooth muscle cell proliferation and migration through the ROCK/MLCK signalling pathway.
    Journal of cellular and molecular medicine, 2019, Volume: 23, Issue:5

    Topics: Animals; Atherosclerosis; Azepines; Becaplermin; Cell Movement; Cell Proliferation; Enzyme Inhibitor

2019
Myosin light chain kinase inhibitor attenuates atherosclerosis and permeability via reduced endothelial tight junction in rabbits.
    International journal of cardiology, 2013, Oct-12, Volume: 168, Issue:5

    Topics: Animals; Aorta; Atherosclerosis; Azepines; Blotting, Western; Endothelium, Vascular; Immunohistochem

2013
Myosin light chain kinase inhibitor ML7 improves vascular endothelial dysfunction via tight junction regulation in a rabbit model of atherosclerosis.
    Molecular medicine reports, 2015, Volume: 12, Issue:3

    Topics: Animals; Atherosclerosis; Azepines; Diet, High-Fat; Disease Models, Animal; Endothelium, Vascular; L

2015